Oncolytics Biotech Inc. has been granted Canadian Patent 2,360,833 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders". The claims describe the use of one or more recombinant reoviruses to treat Ras-mediated proliferative disorders.

"This patent provides the company with additional patent protection for the use of reovirus compositions for cancers and other cellular proliferative disorders in Canada," said Mary Ann Dillahunty, vice president of Intellectual Property for Oncolytics.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical programme includes a variety of phase I/II and phase II human trials using Reolysin, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy.